April 1 (Bloomberg) -- Users of smoking-cessation products such as GlaxoSmithKline Plc’s Nicorette gum will be able to use the products longer and in combination with other therapies under new U.S. Food and Drug Administration labeling rules.

Glaxo and other makers of over-the-counter nicotine- replacement products can seek new labels that would let people continue smoking cigarettes when they start the treatments and use more than one therapy at a time, the FDA said today in a Federal Register notice. The companies can also advise users to talk to doctors if they want to continue use beyond 12 weeks.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access